📊 KALA Key Takeaways
Is KALA BIO, Inc. (KALA) a Good Investment?
Kala Bio is a pre-commercial biotech company with zero revenue and -$27.7M net losses, generating -$28.9M in free cash flow. With negative stockholders' equity of -$8.7M, liabilities exceeding assets, and only ~9 months of cash runway at current burn rates, the company faces imminent solvency risk without significant debt restructuring or capital injection.
KALA BIO is pre-revenue with substantial operating losses, negative equity, and sub-1.0 liquidity, signaling material financial stress. With deeply negative interest coverage and persistent cash burn, the business appears dependent on near-term external financing or a swift, uncertain shift to revenue.
Why Buy KALA BIO, Inc. Stock? KALA Key Strengths
- Retains $21.1M in cash providing near-term operational runway
- Pharmaceutical sector offers potential value creation if pipeline programs advance
- Zero insider selling in past 90 days suggests management confidence
- $21.1M cash provides short-term runway
- Asset-light profile with low capex ($1.46M)
- EPS loss improved YoY, suggesting some cost discipline
KALA Stock Risks: KALA BIO, Inc. Investment Risks
- Negative stockholders' equity of -$8.7M indicates technical insolvency
- Zero revenue with no clear path to commercialization evident in filing data
- Cash burn of $28.9M annually with <12 months liquidity runway remaining
- Liabilities ($33.7M) exceed total assets ($25.0M) by $8.7M
- Current ratio of 0.75x and negative operating cash flow indicate acute liquidity crisis
- Long-term debt of $26.9M cannot be serviced from operations (interest coverage: -19.9x)
- Liquidity shortfall: current ratio 0.75x and negative equity
- Sustained negative FCF (-$28.89M) with zero revenue
- High leverage and -19.9x interest coverage raise refinancing/dilution risk
Key Metrics to Watch
- Monthly cash burn rate and updated runway estimate
- Clinical trial progress and potential partnership announcements
- Debt restructuring negotiations and covenant compliance status
- Capital raise activities or strategic alternatives announcement
- Path to first product revenue
- Operating cash burn (OCF) and cash runway
- Debt service/interest coverage and upcoming maturities
KALA BIO, Inc. (KALA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
KALA Profit Margin, ROE & Profitability Analysis
KALA vs Healthcare Sector: How KALA BIO, Inc. Compares
How KALA BIO, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KALA BIO, Inc. Stock Overvalued? KALA Valuation Analysis 2026
Based on fundamental analysis, KALA BIO, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KALA BIO, Inc. Balance Sheet: KALA Debt, Cash & Liquidity
KALA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: KALA BIO, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-10.15 indicates the company is currently unprofitable.
KALA Revenue Growth, EPS Growth & YoY Performance
KALA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $420.0K | -$8.7M | $-3.41 |
| Q2 2023 | $2.1M | -$10.4M | $-4.36 |
| Q1 2023 | $1.4M | -$14.5M | $-6.99 |
| Q3 2022 | $420.0K | -$28.1M | $19.25 |
| Q2 2022 | $2.1M | -$28.1M | $-0.38 |
| Q1 2022 | $1.4M | -$30.4M | $-0.45 |
| Q3 2021 | $2.2M | -$27.9M | N/A |
| Q2 2021 | $833.0K | -$23.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KALA BIO, Inc. Dividends, Buybacks & Capital Allocation
KALA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for KALA BIO, Inc. (CIK: 0001479419)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KALA
What is the AI rating for KALA?
KALA BIO, Inc. (KALA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KALA's key strengths?
Claude: Retains $21.1M in cash providing near-term operational runway. Pharmaceutical sector offers potential value creation if pipeline programs advance. ChatGPT: $21.1M cash provides short-term runway. Asset-light profile with low capex ($1.46M).
What are the risks of investing in KALA?
Claude: Negative stockholders' equity of -$8.7M indicates technical insolvency. Zero revenue with no clear path to commercialization evident in filing data. ChatGPT: Liquidity shortfall: current ratio 0.75x and negative equity. Sustained negative FCF (-$28.89M) with zero revenue.
What is KALA's revenue and growth?
KALA BIO, Inc. reported revenue of $0.0.
Does KALA pay dividends?
KALA BIO, Inc. does not currently pay dividends.
Where can I find KALA SEC filings?
Official SEC filings for KALA BIO, Inc. (CIK: 0001479419) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KALA's EPS?
KALA BIO, Inc. has a diluted EPS of $-4.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KALA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, KALA BIO, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KALA stock overvalued or undervalued?
Valuation metrics for KALA: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KALA stock in 2026?
Our dual AI analysis gives KALA BIO, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KALA's free cash flow?
KALA BIO, Inc.'s operating cash flow is $-27.4M, with capital expenditures of $1.5M.
How does KALA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.75 (avg: 2).